$PTHS News

Pelthos Therapeutics (PTHS) Stock Fair Value Falls After Analysts Cut Zelsuvmi Launch Estimates

Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos (PTHS) Q2 2026 Earnings Call Transcript

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Pelthos Therapeutics Q2 Earnings Call Highlights

Pelthos Therapeutics Inc (PTHS) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as ...

Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes

Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66